BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 23857972)

  • 61. Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.
    Tanaka M; Takamatsu Y; Anan K; Ohno S; Nishimura R; Yamamoto Y; Masuda N; Mitsuyama S; Tamura K;
    Anticancer Drugs; 2010 Apr; 21(4):453-8. PubMed ID: 20075712
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lapatinib for the treatment of HER2-overexpressing breast cancer.
    Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treatment for anthracycline-pretreated metastatic breast cancer.
    O'Shaughnessy J; Twelves C; Aapro M
    Oncologist; 2002; 7 Suppl 6():4-12. PubMed ID: 12454314
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).
    Li T; Guo M; Gradishar WJ; Sparano JA; Perez EA; Wang M; Sledge GW
    Breast Cancer Res Treat; 2012 Jul; 134(1):345-52. PubMed ID: 22547107
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
    Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
    Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
    Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S
    Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.
    Schott AF; Barlow WE; Albain KS; Chew HK; Wade JL; Lanier KS; Lew DL; Hayes DF; Gralow JR; Livingston RB; Hortobagyi GN
    Oncologist; 2012; 17(2):179-87. PubMed ID: 22267853
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
    Curigliano G; Pivot X; Cortés J; Elias A; Cesari R; Khosravan R; Collier M; Huang X; Cataruozolo PE; Kern KA; Goldhirsch A
    Breast; 2013 Oct; 22(5):650-6. PubMed ID: 23958375
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a phase II study.
    Jakob A; Bokemeyer C; Knop S; Schupp M; Mayer F; Kanz L
    Anticancer Drugs; 2002 Apr; 13(4):405-10. PubMed ID: 11984086
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
    Bellmunt J; Suarez C; Gallardo E; Rodon J; Pons F; Bonfill T; Beltran M; Moya I; Galtes S; Albanell J; Carles J
    Oncologist; 2014 Sep; 19(9):917-8. PubMed ID: 25142843
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer.
    Lin PC; Wang WS; Yang MH; Yen CC; Chao TC; Hsiao LT; Chen PM
    J Chin Med Assoc; 2006 Jul; 69(7):304-9. PubMed ID: 16903643
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
    Park IH; Im SA; Jung KH; Sohn JH; Park YH; Lee KS; Sim SH; Park KH; Kim JH; Nam BH; Kim HJ; Kim TY; Lee KH; Kim SB; Ahn JH; Lee S; Ro J
    Cancer Res Treat; 2019 Jan; 51(1):43-52. PubMed ID: 29458237
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.
    Orphanos G; Alexopoulos A; Malliou S; Ioannidis G; Ardavanis A; Kandylis C; Stavrakakis J; Rigatos G
    J Cancer Res Clin Oncol; 2010 Jan; 136(1):115-21. PubMed ID: 19672628
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
    Baselga J; Costa F; Gomez H; Hudis CA; Rapoport B; Roche H; Schwartzberg LS; Petrenciuc O; Shan M; Gradishar WJ
    Trials; 2013 Jul; 14():228. PubMed ID: 23876062
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
    Levy C; Fumoleau P
    Cancer Treat Rev; 2005; 31 Suppl 4():S17-22. PubMed ID: 16360543
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.
    Cameron D; Casey M; Oliva C; Newstat B; Imwalle B; Geyer CE
    Oncologist; 2010; 15(9):924-34. PubMed ID: 20736298
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer.
    Vrdoljak E; Boban M; Omrcen T; Hrepic D; Fridl-Vidas V; Boskovic L
    Neoplasma; 2011; 58(2):172-8. PubMed ID: 21275468
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials.
    Valero V; Vrdoljak E; Xu B; Thomas E; Gómez H; Manikhas A; Medina C; Li RK; Ro J; Bosserman L; Vahdat L; Mukhopadhyay P; Opatt D; Sparano JA
    Clin Breast Cancer; 2012 Aug; 12(4):240-6. PubMed ID: 22658378
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Capecitabine in elderly patients with metastatic breast cancer.
    De Sanctis R; Quadrini S; Longo F; Lapadula V; Restuccia R; Del Signore E; De Filippis L; Stumbo L; Gori B; Bianco V; Speranza I; Basile ML; Di Seri M
    Tumori; 2012; 98(3):303-7. PubMed ID: 22825504
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
    Martin M; Campone M; Bondarenko I; Sakaeva D; Krishnamurthy S; Roman L; Lebedeva L; Vedovato JC; Aapro M
    Ann Oncol; 2018 May; 29(5):1195-1202. PubMed ID: 29447329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.